U.S. markets closed

HempAmericana, Inc (HMPQ)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0064+0.0004 (+6.67%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0060
Open0.0060
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0054 - 0.0066
52 Week Range0.0010 - 0.0126
Volume5,131,470
Avg. Volume18,114,498
Market Cap277,068
Beta (5Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    HempAmericana Set to Launch CBG Oil Product for Online Sales and Through Alibaba.com Platform

    NEW YORK, NY / ACCESSWIRE / May 22, 2020 / HempAmericana, Inc. (OTC PINK:HMPQ) ("HempAmericana" or the "Company"), an emerging leader in the CBD products market, is excited to announce the upcoming launch of the Company's new Cannabigerol (CBG) oil product, now being laboratory tested for purity and potency. The product will be available for purchase within two weeks on the Company's recently launched e-commerce portal (HempAmericana.store) as well as through its newly established distribution relationship with the Alibaba B2B platform. "CBG has already started to inspire a great deal of interest as an emerging new trend in the cannabinoid supplement marketplace because it has subtle nuances in terms of its interaction with the endocannabinoid system that we are only just beginning to understand," noted Salvador Rosillo, CEO of HempAmericana.